{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:19:46Z","timestamp":1753881586319,"version":"3.41.2"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":178,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Contrast Media &amp; Molecular Imaging"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>In this study, our purpose was to systematically evaluate the efficacy and safety of interleukin\u201023 (IL\u201023)\u2010targeted drugs in the treatment of moderate\u2010to\u2010severe psoriasis and provide an evidence\u2010based reference for clinical treatment. A computer search of PubMed, EMBASE, Web of Science, Cochrane Library, Chinese Journal Full Text Database, Chinese Science and Technology Journal Database, and Wanfang Database was conducted from the establishment of the database to 2021\u201009\u201030. The efficacy of IL\u201023\u2010targeted drugs (trial group) was compared with placebo (control group) in the treatment of psoriasis; i.e., PASI score improvement of 75% or more (PASI 75, PASI 90, and PASI 100) and the safety of randomized controlled trials (RCTs) were collected. Meta\u2010analysis was performed using Rev Man 5.4.3 statistical software after data extraction for clinical studies that met the inclusion criteria. A total of 9 studies were included, all included studies were large multicenter, randomized, double\u2010blind, placebo\u2010controlled studies, and all used correct randomization methods and were of good quality. Meta\u2010analysis showed that the improvement rates of PASI 75, PASI 90, and PASI 100 in the test group were superior to those in the control group (OR\u2009=\u200970.21 (42.25, 166.66), <jats:italic>P<\/jats:italic> &lt; 0.00001), (OR\u2009=\u200978.41 (53.09, 115.79), <jats:italic>P<\/jats:italic> &lt; 0.00001), and (OR\u2009=\u200977.10 (38.61, 153.99), <jats:italic>P<\/jats:italic> &lt; 0.00001), <jats:italic>P<\/jats:italic> &lt; 0.05. However, more adverse effects occurred, and the differences were statistically significant. IL\u201023\u2010targeted drugs have significantly higher response rates compared to placebo in the treatment of psoriasis, and the safety was acceptable.<\/jats:p>","DOI":"10.1155\/2022\/2172980","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:50:14Z","timestamp":1656445814000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Meta\u2010Analysis of the Efficacy and Safety of Interleukin\u201023\u2010Targeted Drugs in the Treatment of Moderate\u2010to\u2010Severe Psoriasis"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-2270","authenticated-orcid":false,"given":"Teng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7625-9842","authenticated-orcid":false,"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.585634"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/erp.09.23"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2021.06.018"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14433"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13802"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-020-01339-9"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16073"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17628"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14504"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.304"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000001163"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31279-5"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2546161"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.020"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14673"},{"key":"e_1_2_8_24_2","first-page":"776","article-title":"Comparison of the Safety and Efficacy of Tumor Necrosis factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis","volume":"18","author":"Green L. J.","year":"2019","journal-title":"Journal of Drugs in Dermatology: Journal of Drugs in Dermatology"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201019666180103140643"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.144"}],"container-title":["Contrast Media &amp; Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmi\/2022\/2172980.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmi\/2022\/2172980.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2022\/2172980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T07:08:16Z","timestamp":1721804896000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/2172980"}},"subtitle":[],"editor":[{"given":"Mohammad Farukh","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1155\/2022\/2172980"],"URL":"https:\/\/doi.org\/10.1155\/2022\/2172980","archive":["Portico"],"relation":{},"ISSN":["1555-4309","1555-4317"],"issn-type":[{"type":"print","value":"1555-4309"},{"type":"electronic","value":"1555-4317"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2022-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2172980"}}